PRX3-targeting drug shows disease control in 67% of mesothelioma patients in early trial
An experimental compound that disables a key antioxidant defence used by mesothelioma tumours has produced encouraging early-phase results, controlling disease progression in two-thirds of participants.
Researchers have published early clinical trial results for an experimental drug designed to exploit a metabolic vulnerability in mesothelioma, the aggressive asbestos-linked cancer of the lining of the lungs and other organs. The compound works by inhibiting PRX3 (peroxiredoxin 3), a mitochondrial antioxidant enzyme that mesothelioma cells depend on to survive high levels of oxidative stress — a condition that normal cells would find lethal. By disabling this defence, the drug pushes tumour cells past a threshold of oxidative damage that they cannot tolerate.
In the early-phase trial, disease control — meaning stable disease or better — was achieved in 67% of participants. Survival data were described by investigators as encouraging, though the study is early-stage and the numbers of participants are small. Mesothelioma is an area of significant unmet need: standard systemic options have offered limited efficacy for decades, and prognosis remains poor.
The researchers note that the PRX3 inhibition strategy may have relevance beyond mesothelioma, since other tumour types also upregulate antioxidant pathways to survive oxidative stress. No institution, journal, or principal investigator is named in the available reporting, so readers seeking the primary data should search for the trial by its compound name or the PRX3 inhibitor designation in clinical trial registries. The findings will require confirmation in larger, randomised studies before the approach can be more broadly evaluated.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Mesothelioma is a cancer linked to asbestos exposure that affects the lining of the lungs and other organs. It has been difficult to treat, and few effective medicines exist. Researchers have been testing a new experimental drug that works by disabling a protective mechanism that mesothelioma tumour cells rely on to survive. In an early clinical trial — a first test in people, with a small number of participants — the drug stopped the cancer from progressing in about two-thirds of patients. Survival results were also described as encouraging by the researchers involved. This is a very early stage of testing. Much larger studies would be needed before this type of treatment could become widely available. Researchers also think a similar approach might one day be useful for other cancers, though that remains to be explored. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source ScienceDaily · 2026-09-17New mesothelioma drug turns cancer's own defenses against it